Exact Sciences Corporation (EXAS) is an American company that specializes in the development and commercial distribution of diagnostic tests for cancer prevention and detection. Their main product is Cologuard, a non-invasive stool test used for detecting colorectal cancer and advanced adenomas. This test allows patients to undergo cancer screening at home, providing significant advantages compared to traditional screening methods such as colonoscopies. In addition to this, Exact Sciences invests in research and development of new diagnostic tests for various types of cancer and other diseases. Exact Sciences Corporation (EXAS) shares may be attractive to investors seeking investments in companies operating in the cancer diagnostics field with an emphasis on innovation and improving healthcare.